-
公开(公告)号:JPS63139171A
公开(公告)日:1988-06-10
申请号:JP28228787
申请日:1987-11-10
Applicant: HOFFMANN LA ROCHE
Inventor: BRANCA QUIRICO , JAUNIN ROLAND , MAERKI HANS P , MARTI FRAENZI , RAMUZ HENRI
IPC: A61K31/415 , A61K31/4184 , A61K31/425 , A61K31/428 , A61K31/44 , A61K31/55 , A61K31/551 , A61P9/00 , A61P9/06 , A61P9/08 , A61P9/10 , A61P9/12 , C07D233/54 , C07D233/64 , C07D235/14 , C07D235/26 , C07D243/14 , C07D277/62 , C07D277/64 , C07D401/06 , C07D471/04 , C07D487/04 , C07D521/00
-
公开(公告)号:JP2000247957A
公开(公告)日:2000-09-12
申请号:JP2000047003
申请日:2000-02-24
Applicant: HOFFMANN LA ROCHE
Inventor: BOS MICHAEL , BRANCA QUIRICO , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K20060101 , A61K31/44 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/444 , A61K31/455 , A61K31/496 , A61P1/00 , A61P9/00 , A61P11/00 , A61P25/00 , A61P25/04 , A61P25/28 , A61P25/30 , A61P27/02 , A61P29/00 , A61P43/00 , C07D20060101 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/63 , C07D213/65 , C07D213/74 , C07D213/75 , C07D213/78 , C07D213/82 , C07D401/04 , C07D401/12 , C07D413/12 , C07D413/14
Abstract: PROBLEM TO BE SOLVED: To obtain a new 4-phenylpyridine derivative which is a neurokinin 1 receptor antagonist and is useful for pain, headache, Alzheimer's disease, multiple sclerosis, amorphinism relaxation, cardiovascular change, swelling, chronic inflammatory diseases, respiratory diseases, and the like. SOLUTION: A compound of formula I [R is H, a lower alkyl, a lower alkoxy, a halogen or the like; R1 is H or a halogen; R2, R2' are each H, a halogen, trifluoromethyl, a lower alkoxy or cyano, or R and R1, R2 and R2' together form CH=CH-CH=CH which may be substituted by one or more alkyls or the like; R3 is H, a lower alkyl or a cycloalkyl; R4 is H, N(R5)2 (R5 is H, a 3-6C cycloalkyl or the like) or the like; R6 is H, OH, a lower alkyl or the like; X is C(O)N(R5) or the like; (n) is 0-4; (m) is 1 or 2]. For example, N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-4-o-tolyl-nicotinamide. The compound of formula I is obtained, for example, by reacting a compound of formula II with a compound of formula III.
-
公开(公告)号:CA2299139C
公开(公告)日:2011-03-29
申请号:CA2299139
申请日:2000-02-23
Applicant: HOFFMANN LA ROCHE
Inventor: BOS MICHAEL , BRANCA QUIRICO , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: C07D213/82 , A61K20060101 , A61K31/44 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/444 , A61K31/455 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61P1/00 , A61P9/00 , A61P11/00 , A61P11/06 , A61P19/02 , A61P25/00 , A61P25/04 , A61P25/28 , A61P25/30 , A61P27/02 , A61P29/00 , A61P43/00 , C07D20060101 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/63 , C07D213/65 , C07D213/74 , C07D213/75 , C07D213/78 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12
Abstract: The present invention relates to compounds of the general formula (see formula I) wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R1 is hydrogen or halogen; or R and R1, when adjacent, may be together -CH=CH-CH=CH-; R2 and R2' are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or R2 and R2', when adjacent, may be together -CH=CH-CH-CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy; R3 and R3' are each hydrogen, lower alkyl or together with the carbon to which they are attached form a cycloalkyl group; R4 is hydrogen, -N(R)2, -N(R5)(CH2)n OH, -N(R5)S(O)2-lower alkyl, -N(R5)S(O)2--phenyl, -N=CH-N(R5)2, -N(R5)C(O)R5 or a cyclic tertiary amine of the group (see formula II) or the group (see formula III); R5 is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl; R6 is hydrogen, hydroxy, lower alkyl, -(CH2)n COO-lower alkyl, -N(R5)CO-lower alkyl, hydroxy-lower alkyl, cyano, -(CH2)n O(CH2)n OH, -CHO or a 5-or 6--membered heterocyclic group, wherein said 5- or 6-membered heterocyclic group is optionally bonded via an alkylene group, X is -C(O)N(R5)-, -(CH2)m O-, -(CH2)m N(R5)-, -N(R5)C(O)-, or -N(R)(CH2)m-; n is 0-4; and m is 1 or 2; with the proviso that the compound is other than 2-(3,5-Bis-trifluoromethyl-phenyl)-N--methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide, and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I show a high affinity to the NK-1 receptor. They may be used for the treatment of diseases, which relate to NK-1 receptor antagonists.
-
公开(公告)号:AT496032T
公开(公告)日:2011-02-15
申请号:AT03026298
申请日:2000-02-15
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , BRANCA QUIRICO , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: C07D213/82 , A61K20060101 , A61K31/44 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/444 , A61K31/455 , A61K31/496 , A61P1/00 , A61P9/00 , A61P11/00 , A61P25/00 , A61P25/04 , A61P25/28 , A61P25/30 , A61P27/02 , A61P29/00 , A61P43/00 , C07D20060101 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/63 , C07D213/65 , C07D213/74 , C07D213/75 , C07D213/78 , C07D401/04 , C07D401/12 , C07D413/12 , C07D413/14
Abstract: The present invention relates to compounds of the general formula wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R is hydrogen or halogen; or R and R may be together -CH=CH-CH=CH-; R and R are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or R and R may be together -CH=CH-CH=CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy; R is hydrogen, lower alkyl or form a cycloalkyl group; R is hydrogen, -N(R )2, -N(R )(CH2)nOH, -N(R )S(O)2-lower alkyl, -N(R )S(O)2-phenyl, -N=CH-N(R )2, -N(R )C(O)R or a cyclic tertiary amine of the group R is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl; R is hydrogen, hydroxy, lower alkyl, -(CH2)nCOO-lower alkyl, -N(R )CO-lower alkyl, hydroxy-lower alkyl, cyano, -(CH2)nO(CH2)nOH, -CHO or a 5-or 6 membered heterocyclic group, optionally bonded via an alkylene group, X is -C(O)N(R )-, -(CH2)mO-, -(CH2)mN(R )-, -N(R )C(O)-, or -N(R )(CH2)m-; n is 0 - 4; and m is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I show a high affinity to the NK-1 receptor. They may be used for the treatment of diseases, which relate to NK-1 receptor antagonists.
-
公开(公告)号:ES2171109A1
公开(公告)日:2002-08-16
申请号:ES200000418
申请日:2000-02-23
Applicant: HOFFMANN LA ROCHE
Inventor: BOS MICHAEL , BRANCA QUIRICO , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER
IPC: A61K20060101 , A61K31/44 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/444 , A61K31/455 , A61K31/496 , A61P1/00 , A61P9/00 , A61P11/00 , A61P25/00 , A61P25/04 , A61P25/28 , A61P25/30 , A61P27/02 , A61P29/00 , A61P43/00 , C07D20060101 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/63 , C07D213/65 , C07D213/74 , C07D213/75 , C07D213/78 , C07D213/82 , C07D401/04 , C07D401/12 , C07D413/12 , C07D413/14 , C07D413/04
Abstract: Derivados de 4-fenil-piridina. Estos compuestos corresponden a la fórmula general (I) en donde los radicales R, R{sup,1}, R{sup,2}, R{sup,2''}, R{sup,3}, R{sup,4}, X, n y m son como se expresan en las reivindicaciones. Estos compuestos muestran una mayor afinidad por el receptor de NK-1. La invención también se refiere a sales derivadas de los compuestos que sean farmaceúticamente aceptables, a medicamentos que contengan uno o más de estos compuestos, y a un proceso para la preparación de los compuestos. Los productos de la invención se pueden usar para el tratamiento de enfermedades relacionadas con antagonistas del receptor de NK-1.
-
公开(公告)号:HK1031223A1
公开(公告)日:2001-06-08
申请号:HK01101744
申请日:2001-03-12
Applicant: HOFFMANN LA ROCHE
Inventor: BOS MICHAEL , BRANCA QUIRICO , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K20060101 , A61K31/44 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/444 , A61K31/455 , A61K31/496 , A61P1/00 , A61P9/00 , A61P11/00 , A61P25/00 , A61P25/04 , A61P25/28 , A61P25/30 , A61P27/02 , A61P29/00 , A61P43/00 , C07D20060101 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/63 , C07D213/65 , C07D213/74 , C07D213/75 , C07D213/78 , C07D213/82 , C07D401/04 , C07D401/12 , C07D413/12 , C07D413/14 , C07D , A61K , A61P
Abstract: The present invention relates to compounds of the general formula wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R is hydrogen or halogen; or R and R may be together -CH=CH-CH=CH-; R and R are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or R and R may be together -CH=CH-CH=CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy; R is hydrogen, lower alkyl or form a cycloalkyl group; R is hydrogen, -N(R )2, -N(R )(CH2)nOH, -N(R )S(O)2-lower alkyl, -N(R )S(O)2-phenyl, -N=CH-N(R )2, -N(R )C(O)R or a cyclic tertiary amine of the group R is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl; R is hydrogen, hydroxy, lower alkyl, -(CH2)nCOO-lower alkyl, -N(R )CO-lower alkyl, hydroxy-lower alkyl, cyano, -(CH2)nO(CH2)nOH, -CHO or a 5-or 6 membered heterocyclic group, optionally bonded via an alkylene group, X is -C(O)N(R )-, -(CH2)mO-, -(CH2)mN(R )-, -N(R )C(O)-, or -N(R )(CH2)m-; n is 0 - 4; and m is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I show a high affinity to the NK-1 receptor. They may be used for the treatment of diseases, which relate to NK-1 receptor antagonists.
-
公开(公告)号:PA8491101A1
公开(公告)日:2001-04-30
申请号:PA8491101
申请日:2000-02-22
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , BRANCA QUIRICO , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K20060101 , A61K9/20 , A61K31/44 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/444 , A61K31/455 , A61K31/496 , A61P1/00 , A61P9/00 , A61P11/00 , A61P25/00 , A61P25/04 , A61P25/28 , A61P25/30 , A61P27/02 , A61P29/00 , A61P43/00 , C07D20060101 , C07D213/26 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/63 , C07D213/65 , C07D213/74 , C07D213/75 , C07D213/78 , C07D213/82 , C07D401/04 , C07D401/12 , C07D401/14 , C07D413/12 , C07D413/14
Abstract: LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA GENERAL EN DONDE R ES HIDROGENO, ALQUILO INFERIOR, ALCOXI INFERIOR, HALOGENO O TRIFLUOROMETILO; R1 ES HIDROGENO O HALOGENO; O R Y R1 PUEDEN SER CONJUNTAMENTE -CH=CH-CH=CH-; R2 Y R2', SON INDEPENDIENTEMENTE, HIDROGENO, HALOGENO, TRIFLUOROMETILO, CIANO O ALCOXI INFERIOR;O R2 Y R2', PUEDEN SER CONJUNTAMENTE -CH=CH-CH=CH-, SUSTITUIDO OPCIONALMENTE POR UNO O DOS SUSTITUYENTES SELECCIONADOS DEL ALQUILO INFERIOR O DEL ALCOXI INFERIOR; R3 ES HIDROGENO,ALQUILO INFERIOR O FORMA UN GRUPO CICLOALQUILO; R4 ES HIDROGENO, -N (R5)2, -N(R5)(CH2)nOH,-N (R5)S(O)2- ALQUILO INFERIOR, -N(R5)S(O)2-FENILO,-N=CH-N(R5)2,-N(R5)C(O)R5 O UNA AMINA TERCIARIA CICLICA DEL GRUPO R5 ES INDEPENDIENTEMENTE, HIDROGENO, C3-6-CICLOALQUILO,BENCILO O ALQUILO INFERIOR; R6 ES HIDROGENO, HIDROXI, ALQUILO INFERIOR , -(CH2)nCOO-ALQUILO INFERIOR, -N(R5)CO-ALQUILO INFERIOR, HIDROXI-ALQUILO-INFERIOR, CIANO,-(CH2)nO(CH2)nOH,-CHO O UN GRUPO HETEROCICLICO DE 5 O 6 MIEMBROS, UNIDO OPCIONALMENTE POR UN GRUPO ALQUILENO, X ES -C(O)N(R5)-,-(CH2)mO-,-(CH2)mN(R5)-,-N(R5)C(O)-, ó -N(R5)(CH2)m-; N ES 0-4; Y M ES 1 ó 2; Y SALES DERIVADAS DE UNA ADICION ACIDA FARMACEUTICAMENTE ACEPTABLES. LOS COMPUESTOS DE LA FORMULA 1 MUESTRAN UNA MAYOR AFINIDAD POR EL RECEPTOR DE NK-1. ESTOS SE PUEDEN USAR PARA EL TRATAMIENTO DE ENFERMEDADES QUE ESTEN RELACIONADAS CON ANTAGONISTAS DEL RECEPTOR DE NK-1.
-
公开(公告)号:IS5381A
公开(公告)日:2000-08-25
申请号:IS5381
申请日:2000-02-22
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , BRANCA QUIRICO , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K20060101 , A61K31/44 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/444 , A61K31/455 , A61K31/496 , A61P1/00 , A61P9/00 , A61P11/00 , A61P25/00 , A61P25/04 , A61P25/28 , A61P25/30 , A61P27/02 , A61P29/00 , A61P43/00 , C07D20060101 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/63 , C07D213/65 , C07D213/74 , C07D213/75 , C07D213/78 , C07D213/82 , C07D401/04 , C07D401/12 , C07D413/12 , C07D413/14 , A61K31/442
-
公开(公告)号:ZA200000894B
公开(公告)日:2000-08-24
申请号:ZA200000894
申请日:2000-02-23
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , BRANCA QUIRICO , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K20060101 , A61K31/44 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/444 , A61K31/455 , A61K31/496 , A61P1/00 , A61P9/00 , A61P11/00 , A61P25/00 , A61P25/04 , A61P25/28 , A61P25/30 , A61P27/02 , A61P29/00 , A61P43/00 , C07D20060101 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/63 , C07D213/65 , C07D213/74 , C07D213/75 , C07D213/78 , C07D213/82 , C07D401/04 , C07D401/12 , C07D413/12 , C07D413/14 , C07D , A61K
Abstract: The present invention relates to compounds of the general formula wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R is hydrogen or halogen; or R and R may be together -CH=CH-CH=CH-; R and R are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or R and R may be together -CH=CH-CH=CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy; R is hydrogen, lower alkyl or form a cycloalkyl group; R is hydrogen, -N(R )2, -N(R )(CH2)nOH, -N(R )S(O)2-lower alkyl, -N(R )S(O)2-phenyl, -N=CH-N(R )2, -N(R )C(O)R or a cyclic tertiary amine of the group R is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl; R is hydrogen, hydroxy, lower alkyl, -(CH2)nCOO-lower alkyl, -N(R )CO-lower alkyl, hydroxy-lower alkyl, cyano, -(CH2)nO(CH2)nOH, -CHO or a 5-or 6 membered heterocyclic group, optionally bonded via an alkylene group, X is -C(O)N(R )-, -(CH2)mO-, -(CH2)mN(R )-, -N(R )C(O)-, or -N(R )(CH2)m-; n is 0 - 4; and m is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I show a high affinity to the NK-1 receptor. They may be used for the treatment of diseases, which relate to NK-1 receptor antagonists.
-
公开(公告)号:NO20000885D0
公开(公告)日:2000-02-23
申请号:NO20000885
申请日:2000-02-23
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , BRANCA QUIRICO , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K20060101 , A61K31/44 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/444 , A61K31/455 , A61K31/496 , A61P1/00 , A61P9/00 , A61P11/00 , A61P25/00 , A61P25/04 , A61P25/28 , A61P25/30 , A61P27/02 , A61P29/00 , A61P43/00 , C07D20060101 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/63 , C07D213/65 , C07D213/74 , C07D213/75 , C07D213/78 , C07D213/82 , C07D401/04 , C07D401/12 , C07D413/12 , C07D413/14 , C07D
Abstract: The present invention relates to compounds of the general formula wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R is hydrogen or halogen; or R and R may be together -CH=CH-CH=CH-; R and R are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or R and R may be together -CH=CH-CH=CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy; R is hydrogen, lower alkyl or form a cycloalkyl group; R is hydrogen, -N(R )2, -N(R )(CH2)nOH, -N(R )S(O)2-lower alkyl, -N(R )S(O)2-phenyl, -N=CH-N(R )2, -N(R )C(O)R or a cyclic tertiary amine of the group R is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl; R is hydrogen, hydroxy, lower alkyl, -(CH2)nCOO-lower alkyl, -N(R )CO-lower alkyl, hydroxy-lower alkyl, cyano, -(CH2)nO(CH2)nOH, -CHO or a 5-or 6 membered heterocyclic group, optionally bonded via an alkylene group, X is -C(O)N(R )-, -(CH2)mO-, -(CH2)mN(R )-, -N(R )C(O)-, or -N(R )(CH2)m-; n is 0 - 4; and m is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I show a high affinity to the NK-1 receptor. They may be used for the treatment of diseases, which relate to NK-1 receptor antagonists.
-
-
-
-
-
-
-
-
-